

State update: substance use and overdose

Tom Jeanne, MD, MPH Deputy State Health Officer Deputy State Epidemiologist

Columbia Pacific CCO Conference October 9, 2023




Setting the stage

- Overview of substance use data & trends in Oregon
- Measure 110 and BHRNs
- Emerging issues: fentanyl and xylazine
- Program and policy efforts
- Summary




The changing overdose epidemic



- Fewer deaths & overdoses from Rx medications
- More deaths & overdoses from illicit drugs



Risky opioid prescribing practices continue to decrease




Source: Oregon Prescription Drug Monitoring Program



Drug use and overdose data




Overdose deaths from stimulants and synthetic opioids are rising



Source: Oregon Vital Records (Deaths), OHA Center for Health Statistics, 2022 (provisional data)

Fentanyl and methamphetamine account for most unintentional overdose deaths in 2022


Unintentional/undetermined drug overdose deaths by drug and quarter, Oregon, July 2019 - Dec 2022*





7


Fentanyl + methamphetamine account for more than 1/3 of unintentional overdose deaths in





Source: Oregon State Unintentional Drug Overdose Reporting System (SUDORS), 2022 provisional data

Some groups are disproportionately impacted by overdose deaths





Fentanyl overdose deaths by age: 2020–2022

Unintentional/undetermined fentanyl overdose deaths by age, Oregon, 2020-2022*


Year	Ages 0-17	Ages 18-24	Ages 25-44	Ages 45-64	Ages >=65	Total
2020	5	44	128	46	<5	227
2021	12	60	265	152	23	512
2022	15	60	458	273	36	842

Count of deaths where fentanyl was listed as cause of death (may be found in combination with other drugs)

Source: SUDORS. 2022 data are preliminary counts and subject to change



Unintentional and undetermined drug overdose death rates (per 100,000 residents) by County in Oregon, 2022





Source: Oregon State Unintentional Drug Overdose Reporting System (SUDORS), 2022 provisional data


Characteristics of decedents (2022)

- 69.2% had a documented history of past or current drug use, and no documented history of alcohol use problems
- 35.9% had a diagnosed mental illness
- 17.1% had documented alcohol use problems; alcohol identified as a cause of death for 12.9% (among other substances)
- 19.6% were determined to be houseless at time of overdose
- 78.3% had no documentation of current treatment for mental health issues or substance abuse




Oregon vs other states: drug overdose deaths

- 2021 data from SUDORS (latest available final data)
- Oregon's age-adjusted drug overdose death rate was 9th *lowest* out of 32 states






Oregon vs other states: drug overdose deaths





Oregon vs other states: drug overdose deaths




Drug overdose deaths in Oregon: Latest data

- Comparing Oct 2022 to March 2023 to Oct 2021 to March 2022, the unintentional / undetermined drug overdose deaths increased by 46 percent, from 543 to 793
- For the same period, **fentanyl** overdose deaths increased by nearly 93 percent, from 305 to 587




Drug overdose deaths in Oregon: Latest data






Emergency department & urgent care visits for opioid overdose increased in 2022–23



Source: Electronic Surveillance System for the Early Notification of Community-Based Epidemics (ESSENCE)

Youth data


Figure 2: Percentage of youth (ages 12-17) with a documented substance use disorder in the past year, **Oregon** and **national**





Youth data


Figure 1: 2022 Student Health Survey data





Oregon vs other states: drug use disorder

Figure 21a. Drug Use Disorder in the Past Year: Among People Aged 12 or Older; by State, Percentages, 2021




Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2021.





Oregon vs other states: alcohol use disorder

Figure 24a. Alcohol Use Disorder in the Past Year: Among People Aged 12 or Older; by State, Percentages, 2021



Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2021.



Source: NSDUH, 2021

Excessive alcohol use

- Excessive alcohol use the third leading cause of preventable death in Oregon
 - Over 2,000 deaths each year and rising
 - \$4.8 billion in healthcare expenses, motor vehicle crashes, criminal justice costs and lost productivity
- Per capita consumption of alcohol in Oregon is higher than the national average
 - >1 in 5 Oregon adults report excessive drinking in the past month
 - ~577 drinks are consumed per person age 14+ in Oregon every year




Measure 110 in context



Measure 110

- Goal: establish a more equitable health-based and effective approach to SUD in Oregon
- Passed November 2020
- Made changes to the criminal justice system and the behavioral health system
 - Decriminalization happened fast (February 2021)
 - Funding of Behavioral Health Resource Networks happened slowly (began May 2022)




Measure 110

- Established Behavioral Health Resource Networks (BHRNs)
 - 42 BHRNs, at least one in each county
 - Each BHRN includes partners that together cover a full spectrum of services including screening and assessments, peer services, harm reduction interventions, low barrier substance use treatment, housing, and employment supports
- Created the Oversight and Accountability Council (OAC)
 - 20 members with professional and lived experience with substance use
 - Approve and oversee grants to BHRNs
- Administered by OHA



Measure 110 Data Dashboard



Сог	ınty	County		
A	LL	Clatsop, Columbia, - Tillamook		
Number of BHRNs	Number of BHRNs Number of			
10	Organizations	2	Organizations	
42	233	3	18	
Award Amount	Percent of Total Funds	Award Amount	Percent of Total Funds	
60.051.4	Available	64.20.4	Available	
\$265M	100.0%	\$12M	2.9%	
Total Population	Percent of Total	Total Population	Percent of Total	
	Population		Population	
4M	100.0%	119K	2.8%	

Tribal grantees and allocation information not displayed on map.

Number of Tribal	Tribal Allocation	
Grants	\$11.4M	
11	<i> </i>	

https://www.oregon.gov/oha/HSD/AMH/Pages/Measure110.as



DX

Measure 110 Data Dashboard


Client Engagement in BHRN Partner Services

Data displayed on this page was reported by BHRN Partners during quarters 1 (7/1/22-9/30/22), 2 (10/1/22-12/31/22), and 3 (1/1/23-3/31/23) of their grants. BHRN Partners report the number of clients they serve, and the number of service encounters they have with their clients, as a measure of overall engagement. The chart below shows that statewide, the largest numbers of clients and encounters were reported in the areas of Peer Support and Harm Reduction for all quarters. Additionally, the number of clients increased statewide each quarter in all service areas. **Use the buttons below** to view either the number of clients or the number of service encounters. **Use the menu on the right to filter for a** specific county.


Number of

Encounters

BHRN Client Counts by Service Area - All Counties



Number of Clients



Trends since Measure 110

- It's too early to attribute population health outcomes to Measure 110
 - Changes take time to be reflected in health outcomes (compare to tobacco Master Settlement Agreement)
 - Given numerous changes, isolating the effect of M110 will be difficult
- So why are drug seizures, drug hospitalizations, and overdose deaths increasing so rapidly?




Figure: Counterfeit oxycodone pills.




Figure 10. Drug-related Deaths from all 50 States and District of Columbia, 3-month Moving Average from 2008 through September 2022 (not age adjusted)

Drugrelated deaths are increasing in many states

https://pdxscholar.lib rary.pdx.edu/ccj_fac/ 114/



Joshi S et al. – One-Year Association of Drug Possession Law Change With Fatal Drug Overdose in Oregon and Washington



Oregon vs synthetic Oregon (A) and Washington vs synthetic Washington (B), January 2018-March 2022. The vertical line represents the implementation of Measure 110 and the *Blake* decision. All control units reflect an unweighted

average rate of fatal drug overdose over the study period, inclusive of all 49 control units. The vertical line indicates the implementation of the drug policy change.



Joshi S et al. – One-Year Association of Drug Possession Law Change With Fatal Drug Overdose in Oregon and Washington

- This study found no evidence of an association between decriminalization of drug possession in Oregon and Washington and fatal drug overdose rates
- However, the study only had available about one year of overdose data post-M110 (through March 2022)




Major contextual factors – a complex landscape

- Measure 110 took effect in February 2021
- BHRN funding began May 2022
 - Behavioral health workforce gaps and efforts to address gaps
- COVID-19 pandemic: hugely disruptive
- Law enforcement practice changes
- Medicaid 1115 waiver to expand SUD services, fund housing
- Opioid settlement funding efforts
- Fentanyl: massive increase in supply in western states

Fentanyl has rapidly surpassed other opioids in Oregon


Fentanyl Seizures




From Oregon–Idaho HIDTA 2022 Annual Report



Fentanyl has rapidly surpassed other opioids in Oregon



2022 Drug Seizure Incidents Oregon-Idaho HIDTA Initiatives



Source: HIDTA Performance Management Process – Number of seizures related to drug type for 2022. Fentanyl seizure amounts in 2021 and 2022 comparison – Accessed 02/17/2023

From Oregon–Idaho HIDTA 2024 Threat Assessment



Fentanyl Adulterated with Xylazine



Xylazine overview

- A veterinary sedative and central nervous system (CNS) depressant
- Increasingly being found as an adulterant in fentanyl
- Not an opioid and not affected by naloxone
- Complicates overdoses, causes serious wounds, and has potential for physical dependency and withdrawal
- Can cause overdose death by itself but is usually found in combination with other drugs such as heroin, fentanyl, and cocaine




Xylazine Wounds


- Xylazine wounds have been reported from injecting, smoking and snorting, and they need medical care.
- Wounds can start anywhere there is open skin, and often start as shallow looking blisters and ulcers that can progress rapidly.



 Wounds differ from abscesses and can rapidly spread into muscles, tendons, and bones, requiring prolonged medical care to heal.







Abbreviations: IMF = illicitly manufactured fentanyl; SUDORS = State Unintentional Drug Overdose Reporting System.

* A drug was considered involved or co-involved if it was listed as a cause of death on the death certificate or medical examiner or coroner report.

⁺ Fentanyl was classified as likely illicitly manufactured using toxicology, scene, and witness evidence. For the 8% of deaths involving fentanyl that had insufficient evidence for classification as illicit or prescription, fentanyl was classified as illicit because the vast majority of fentanyl overdose deaths involve illicit fentanyl. All fentanyl analogs except alfentanil, remifentanil, and sufentanil, which have legitimate human medical use, were included as IMFs.

Month and year

[§] Connecticut, Delaware, District of Columbia, Georgia, Illinois, Maine, Massachusetts, Minnesota, Nevada, New Hampshire, New Jersey, New Mexico, Ohio, Oklahoma, Pennsylvania, Rhode Island, Utah, Vermont, Virginia, Washington, and West Virginia. Illinois, Pennsylvania, and Washington reported deaths from counties that accounted for ≥75% of drug overdose deaths in the state in 2017 per SUDORS funding requirements; all other jurisdictions reported deaths from the full jurisdiction. Jurisdictions were included if data were available for each 6-month period (January–June 2019, July–December 2019, January–June 2021, July–December 2021, and January–June 2022), and toxicology reports were available for ≥75% of deaths in the included period or periods. Analysis was restricted to decedents with an available toxicology report or with xylazine listed as a cause of death on the death certificate.





Numbers of detections and deaths involving xylazine among drug overdose deaths in Oregon

Year	Forensic detection of Xylazine	Overdose deaths implication of Xylazine		
2020	2	0		
2021	9	1		
2022	10	2		
2023*	5	5		
* 2023 data are very preliminary				

All deaths involving Xylazine were co-involved with fentanyl

Source: SUDORS



Oregon's Xylazine Prevention & Response

- <u>Health Intelligence Briefing (HIB)</u>: Convened a HIB in May 2023 to discuss OHA's public health surveillance mechanisms, response strategies, and needs related to preparation and response planning
- <u>Cross-Divisional Collaboration</u>: Formed a cross-division workgroup in June 2023 to coordinate OHA's fentanyl-xylazine response
- <u>Surveillance & Response Preparation:</u> Finalizing the Oregon Overdose Response Protocol and Fentanyl-Xylazine Overdose Surveillance Plan
- <u>Communications</u>: Formed a cross-division subcommittee to develop stakeholder-specific resources. Clinician and public guidance coming soon.




Program & Policy Efforts

How we can bolster our response to the statewide overdose crisis



SUD Continuum of Care Framework



- Promotion increases resilience and well-being for everyone
- **Prevention** reduces the risk of developing high-risk behaviors
- Treatment diagnoses and provides services to individuals with SUD
- **Recovery** links individuals to positive, supportive activities, environments, and opportunities to support long-term treatment



Conceptual Framework of Public Health & Health System SUD Syndemic Approach Key Strategies

- Reduce SUD stigma
- Improve community infrastructure
- Collaborate across sectors

- ✐

CCOs!

Prevent acute lifethreatening outcomes Utilize evidence and data to make decisions Increase protective factors to prevent SUD Reduce risk of harm from substance use for people living with SUD Improve quality of life for people with SUD Diagno COOS! Substance I Naloxone Overdose (OD) and Suicide Drug checking IDU-related infections: skin and soft Sterile syringes tissue infections, sepsis, endocarditis HAV/HBV Vaccine Exposure of unborn infants to Condoms and HIV nPEP drugs, Safe injection supplies and SCF alcohol, syphilis, hepatitis B OD and suicide survivor response Diagnose and treat conditions **Opioid Treatment Programs (OTP)** and infections Integrated SUD screenings in primary care Integrated, peer-based rapid HIV, HCV and Substance Use Disorders (SUD) syphilis screening and linkage to care SUD Treatment and Long-term Recovery Support Alcohol Use Disorders (AUD) MAT, HIV PrEP, hepatitis C, HIV and STI treatment in primary care Hepatitis C, HIV and syphilis Primary Care Provider SUD/AUD, buprenorphine, HIV and HCV **IDU-related infections** training, mentoring and support network

40^{cus}onlongterm^c **Policy, environment and** social determinants

Insurance coverage and parity for OTP, SUD and behavioral health care/

Laws, rules and policies that support health,

Community resilience and

Peer-based substance use and disease prevention, risk and harm reduction Community and cross-sector training about SUD, infectious disease and harm reduction Increase number of OTP/SUD, behavioral health care providers, peer and community recovery Effective pain treatment, safe prescribing, use of PDMP and overdose reporting data Laws, rules and policies that promote safety, decrease overdose, suicide and infection risk and support Reduce stigma, change social norms and strengthen social supports Prevent and address Adverse Childhood Events (ACEs) trauma and toxic

immediate

*individual-level a

safety Model adapted from the Association of State and Territorial Health Officers (ASTHO) Opioid Framework. Contact judith.m.leahv@state.or.us

Oregon's 1115 Medicaid waiver

- \$138 million to strengthen state capacity; OHA is adding 131 positions to address health-related social needs
- Extended Oregon Health Plan (OHP) eligibility for young children, youth, and adults
 - Continuous OHP eligibility and enrollment for children up to age six
 - Two years of continuous enrollment for OHP members ages six and older
- Health-related social needs (HRSNs) supports including housing, nutrition and climate supports
- Coverage for young adults with special health care needs up to age 26

Opioid settlements

Estimated total of >\$325 million coming to Oregon

55% to Cities and Counties

- Approx. \$179 million paid by the national settlement administrator directly to cities and counties (pop. >10,000)
- Allocation decisions are made locally
- DOJ will publish and present annual report with public meeting
- 45% to State of Oregon Opioid Settlement Prevention, Treatment & Recovery Fund
 - Approx. \$146 million in 18 payments through 2038
 - OHA staffing the state portion of the settlement
 - Allocation decisions made by Opioid Settlement Prevention, Treatment, and Recovery Board
 - All meetings are public: <u>Oregon.gov/opioidsettlement</u>

Opioid settlement priority strategies for all funds (state and local)

Prevention programs	Naloxone distribution and education	Syringe services and other harm reduction programs	Medication for opioid use disorder (MOUD/MAT)		
Treatment and services for pregnant and postpartum people	Treatment and services for incarcerated populations	Neonatal abstinence syndrome treatment and services	Warm handoff recovery programs and services		
Leadership, planning, and coordination					

State portion of opioid settlement funds

- 2023 approximate total: \$62M
- 2024: \$12.1M
- 2025: \$15.3M (Payments will come in through 2038)
- On March 1, the Opioid Settlement Prevention, Treatment, and Recovery Board allocated:
 - \$4M for a statewide data system to collect, analyze and publish data about the availability and efficacy of substance use prevention, treatment and recovery services
 - \$13M to Save Lives Oregon, to expand access to naloxone and harm reduction supplies

A comprehensive response to addressing overdose/polysubstance use in Oregon

- The Alcohol and Other Drug Prevention and Education Program (ADPEP) funds primary prevention programs in every tribe and county in Oregon
- Local & Culturally Specific Overdose Prevention
 - Tribal Opioids and Other Drugs Training Academy
 - Funding to Local Public Health Authorities
 - Funding to Community Based Organizations (CBOs)



Pain Management & Safer Opioid Prescribing

- PINPOINT: Statewide clinical quality improvement project for safe pain treatment and opioid prescribing in primary care
- Heal Safely: Non-opioid acute pain management campaign
- Oregon Pain Management Commission Training for providers
- Oregon Pain Guidance for patients and providers



Harm Reduction

- Save Lives Oregon: Harm reduction resource hub and clearinghouse to provide lifesaving supplies to local organizations and tribal communities serving people who use drugs <u>www.savelivesoregon.org</u>
- Reverse Overdose Oregon: Media campaign to empower employers and bystanders to recognize and respond to overdoses in the workforce by administering Naloxone
 - Over 4000 overdose reversals reported with earlier SAMHSA State Targeted Response (STR) and State Opioid Response (SOR)-1 funded naloxone alone



Health Systems Initiatives - Substance Use Treatment

- Medication Assisted Treatment Expansion
 - Since 2017, established/expanded services in 7 opioid treatment programs and 12 Office-Based Opioid Treatment sites
- ECHO Network
 - Rural providers trained on OUD issues through Project ECHO
 - 749 providers have participated since 2017







Key Takeaways

- Overdoses have rapidly increased in Oregon since 2020. Fentanyl has surpassed methamphetamine as the most frequent drug involved in overdose deaths accounting for 90% of opioid overdose deaths in 2022.
- Overdoses involving multiple drugs, including alcohol (polysubstance overdoses), now account for more than half of all fatal overdoses.
- Overdose death disparities continue to worsen for Oregon's American Indian/Alaska Native and Black communities, who experienced overdoses at more than double the rate of White communities in 2022.



Key Takeaways (continued)

- Xylazine has been found in a small but increasing number of overdose deaths since 2020. So far, all overdose deaths in Oregon where xylazine was present also involved fentanyl.
- OHA is monitoring xylazine prevalence and incorporating fentanyl-xylazine into existing response strategies.
- Oregon's surveillance systems are imperfect and do not adequately capture overdoses or the contributing substances in real-time.
- There are solutions to expand data collection and improve data quality, requiring cross-sector coordination and new resources.



Key Takeaways (continued)

- OHA is well positioned to mobilize resources to address this crisis as part of a comprehensive, polysubstance use response.
- State leadership can advance cross-sector infrastructure that includes tribal nations, communities, and people with lived experiences.
- CCOs will continue to play a key role in substance use prevention, treatment, and recovery



Looking ahead

- Oregon needs system transformations to comprehensively address the complex factors contributing to substance use and overdose
 - Integrated harm reduction approaches across the substance use disorder continuum of prevention, care, treatment and recovery
 - Improved culturally specific resources and services
 - Community-level prevention interventions to address intergenerational substance use and root causes of factors that contribute to substance use and overdose, including racism, stigma and the many forms of trauma



Where to find data

- Prescribing and Drug Overdose Data Dashboard: State and county-level data on controlled substance prescribing and drug overdose health outcomes
- Overdose Prevention Dashboard: Mortality; emergency department and hospital discharge data; and annual, statewide, county- level, and demographic trends for 11 drug categories, including fentanyl, heroin, and stimulants.
- Opioid Overdose Public Health Surveillance Update: Quarterly public report of statewide opioid overdose death and hospitalization data



Where to find OHA data

- Annual legislative report: Summarizes overdose burden in Oregon, as required by ORS 432.141; 2023 report in progress with expected release in September 2023
- Local public health authority and tribal health authority quarterly reports, which summarize overdose death and hospitalization data by county



Thank you

- OHA Injury and Violence Prevention

 IVPP.General@odhsoha.oregon.gov
- Tom Jeanne
 - Thomas.L.Jeanne@oha.oregon.gov

